# 3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI

Study · id `cardio:ct-nct04570345` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04570345](<https://clinicaltrials.gov/study/NCT04570345>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04570345

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1002 participants.

## Technical summary

Registry record NCT04570345. Randomized; no masking; primary purpose treatment. Start 2021-01-01 (anticipated); primary completion 2021-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1002 participants (planned count; ClinicalTrials.gov record NCT04570345, source copy `cardio:ctgov-nct04570345-2020-12-22`, retrieved 2026-10-26)
- Planned start: 2021-01-01 (anticipated) (ClinicalTrials.gov record NCT04570345, source copy `cardio:ctgov-nct04570345-2020-12-22`, retrieved 2026-10-26)
- Primary completion: 2021-08-31 (anticipated) (ClinicalTrials.gov record NCT04570345, source copy `cardio:ctgov-nct04570345-2020-12-22`, retrieved 2026-10-26)
- Completion: 2022-08 (anticipated) (ClinicalTrials.gov record NCT04570345, source copy `cardio:ctgov-nct04570345-2020-12-22`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04570345, source copy `cardio:ctgov-nct04570345-2020-12-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04570345-2020-12-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: 3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
- Acronym: BULK-STEMI
- Condition: ST Elevation Myocardial Infarction
- Intervention (Drug): ticagrelor monotherapy
- Intervention (Drug): Aspirin with P2Y12 receptor inhibitor
- Lead sponsor: Dong-A University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Dong-A University (`cardio:org-dong-a-university`)

## Provenance

Content hash: f4f1fd7c89bf8fc6e4c9bb4a40be2ed2c4cee6e1dca8cfb40dbec47c030e33f6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
